Opioid Use Disorder Market by Drug Type (Buprenorphine, Methadone, and Naltrexone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales): Global Opportunity Analysis and Industry Forecast, 2021–2030

Opioid is used for pain relief in patients with long-term pain symptoms. They often have a depressant effect on the central nervous system (CNS) and have the potential to cause euphoria. This is why the long-term use of opioids can make the person get dependent on them and become addicted; this dependence is known as opioid use disorder. In general, two types of patients are known to suffer from opioid use disorder, patients addicted to non-medical opioids and patients addicted to medical opioids. The most commonly abused opioids include oxycodone, hydrocodone, codeine, fentanyl, and morphine.

Market Scope and Structure Analysis

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

However, with COVID-19 the supply chain of raw materials required to manufacture pharmaceutical products for opioid use disorder has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining, as manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the opioid use disorder market.

Top Impacting Factors

The number of patients suffering from severe pain is increasing worldwide. This has led to an increased number of prescriptions for painkillers which often have opioids. Therefore, this factor is contributing to the growth of the opioid use disorder market.

Various forms of diseases such as cancer and cardiovascular diseases often cause severe and ongoing pain to the patients even after their treatments. Thus, alarming rise in the prevalence of such diseases is acting as a key driver of the global opioid use disorder market.

The number of people suffering from opioid addiction has significantly increased in recent years, which has led to the involvement of many government bodies and nongovernmental agencies, thus boosting the growth of the market.

However, one of the factors that can impede the growth of the opioid use disorder market is the side effects that may arise with the use of drugs in the treatment of opioid addiction.

Key Market Trends

The methadone segment of the opioid use disorder market is anticipated to register a low growth rate during the forecast period due to increasing number of generic product offerings and lack of new products in this segment.

The naltrexone segment of the market is expected to have a low market share owing to comparatively less number of product offerings.

In June 2020, Indegene, Inc. partnered with Titan Pharmaceuticals, Inc. in establishing a digital marketing program throughout the U.S. to increase their competence in the provision of their probuphine implant for opioid addiction patients.

In 2019, Dr. Reddy’s Laboratories announced the re-launch of its naloxone and buprenorphine sublingual film after the organization got a favorable ruling in its patent litigation.

Key Segments Covered

Key Benefits of the Report

• This study presents the analytical depiction of the opioid use disorder industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Opioid Use Disorder Report

• Which are the leading players active in the opioid use disorder market?
• How is each segment of the market expected to grow during the forecast period?
• What are the adoption trends for the opioid use disorder market in emerging economies and established economies across the world?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps in the market?
• What are the impacts of COVID-19 on the industry?
• What is opioid use disorder?
• What are the current and predicted trends of the market?

 Key Market Segments

 Key Market Players

• Indivior PLC
• Alkermes PLC
• Teva Pharmaceutical Industries Ltd.
• MediciNova, Inc.
• Hikma Pharmaceuticals
• Orexo AB
• Camurus AB
• Omeros Corporation
• Titan Pharmaceuticals, Inc.
• BioDelivery Sciences International, Inc.